{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:50:30Z","timestamp":1781743830580,"version":"3.54.5"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007489","name":"Bausch + Lomb","doi-asserted-by":"crossref","award":["Study funding; funding for editorial\/medical writing assistance"],"award-info":[{"award-number":["Study funding; funding for editorial\/medical writing assistance"]}],"id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The aim of this study was to assess the long-term safety and efficacy of perfluorohexyloctane (PFHO) ophthalmic drop (formerly NOV03) for treatment of dry eye disease (DED).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>KALAHARI was a phase 3, multicenter, single-arm, open-label extension study in patients aged 18 years or older with DED associated with Meibomian gland dysfunction who completed the randomized, double-masked, hypotonic saline-controlled GOBI study. Patients instilled 1 drop of PFHO (MIEBO, Bausch + Lomb) 4 times daily in both eyes for 52 weeks. Safety assessments included adverse events, best-corrected visual acuity, slit-lamp biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points included change from GOBI study baseline in total corneal fluorescein staining and eye dryness score (0\u2013100 visual analog scale).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 208 patients from GOBI (PFHO [n = 97]; saline [n = 111]) were rolled over into KALAHARI. Twenty-nine patients (13.9%) had \u22651 ocular adverse event, with most being mild or moderate in severity; the most common ocular adverse events were vitreous detachment (1.9%), allergic conjunctivitis (1.4%), blurred vision (1.4%), and increased lacrimation (1.4%). Other safety end points were unremarkable. For patients continuing PFHO from GOBI, improvements in total corneal fluorescein staining and visual analog scale dryness scores observed in GOBI were maintained throughout KALAHARI. Patients treated with saline in GOBI and switched to PFHO in KALAHARI showed improvements in total corneal fluorescein staining and visual analog scale scores by week 4 that were maintained for the rest of the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PFHO was safe and well tolerated and maintained efficacy for improving signs and symptoms of DED in this year-long study of patients with DED associated with Meibomian gland dysfunction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000003418","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:08:46Z","timestamp":1699006126000},"page":"1100-1107","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Long-Term Safety and Efficacy of Perfluorohexyloctane Ophthalmic Solution for the Treatment of Patients With Dry Eye Disease: The KALAHARI Study"],"prefix":"10.1097","volume":"43","author":[{"given":"Eugene E.","family":"Protzko","sequence":"first","affiliation":[{"name":"Seidenberg Protzko Eye Associates, Havre de Grace, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Segal","sequence":"additional","affiliation":[{"name":"Private Practice, Delray Beach, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Korenfeld","sequence":"additional","affiliation":[{"name":"Comprehensive Eye Care, Ltd, Washington, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[{"name":"Novaliq GmbH, Heidelberg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Vittitow","sequence":"additional","affiliation":[{"name":"Clinical Affairs, Bausch + Lomb, Bridgewater, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease: a systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1167\/iovs.16-19419","article-title":"Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments","volume":"57","author":"Nichols","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","article-title":"Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study","volume":"31","author":"Lemp","year":"2012","journal-title":"Cornea"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.survophthal.2022.01.010","article-title":"Metabolomics and lipidomics approaches in human tears: a systematic review","volume":"67","author":"Khanna","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/bjophthalmol-2015-307415","article-title":"Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction","volume":"100","author":"Baudouin","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ICL.0000000000000680","article-title":"A review on evidence-based treatments for meibomian gland dysfunction","volume":"46","author":"Lam","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40123-023-00669-1","article-title":"Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape","volume":"12","author":"Sheppard","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jtos.2019.02.012","article-title":"Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review","volume":"17","author":"Holland","year":"2019","journal-title":"Ocul Surf"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and safety of OC-01 (varenicline solution) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3 randomized trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","article-title":"A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease","volume":"40","author":"Tauber","year":"2021","journal-title":"Cornea"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","article-title":"NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study","volume":"130","author":"Tauber","year":"2023","journal-title":"Ophthalmology"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","article-title":"NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study","volume":"252","author":"Sheppard","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaophthalmol.2023.0270","article-title":"Perfluorohexyloctane eye drops for dry eye disease associated with meibomian gland dysfunction in Chinese patients: a randomized clinical trial","volume":"141","author":"Tian","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bjophthalmol-2015-306930","article-title":"Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up","volume":"100","author":"Straub","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40123-022-00487-x","article-title":"Real-world effectiveness, tolerability and safety of cyclosporine A 0.1% cationic emulsion in severe keratitis and dry eye treatment","volume":"11","author":"Geerling","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R25-20250723","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jop.2019.0092","article-title":"Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial","volume":"36","author":"Schmidl","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","volume":"17","author":"Agarwal","year":"2019","journal-title":"Ocul Surf"},{"key":"R27-20250723","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.curtheres.2023.100704","article-title":"In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease","volume":"98","author":"Vittitow","year":"2023","journal-title":"Curr Ther Res Clin Exp"},{"key":"R28-20250723","first-page":"2656","article-title":"Ocular and systemic distribution of 14C- perfluorohexyloctane following topical ocular administration to rabbits [abstract]","volume":"59","author":"Kr\u00f6sser","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:04:16Z","timestamp":1753279456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000003418","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"2023-07-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}